I.F.O. Istituti Fisioterapici Ospitalieri

The I.F.O. Istituti Fisioterapici Ospitalieri in Rome conducts a large program in oncology, with strong activity across non-small cell lung cancer, breast cancer, melanoma, ovarian cancer, and other advanced solid tumors. These studies are mainly aimed at testing new treatment options, improving disease control, and comparing modern therapies with current standards of care.

• Advanced and metastatic non-small cell lung cancer, including molecularly selected subtypes
• Breast cancer, especially hormone receptor-positive and high-risk early disease
• Melanoma, ovarian cancer, and other difficult-to-treat solid tumors
• Evaluation of new immunotherapy, targeted therapy, and combination treatment strategies

Much of the research focuses on better outcomes for patients with cancers driven by specific genetic changes, while also exploring whether newer approaches can extend survival or delay recurrence.

One of the site’s most active areas is thoracic oncology, with many trials in lung cancer and small cell lung cancer. The work includes studies in newly diagnosed, recurrent, metastatic, and biomarker-defined disease, often comparing innovative targeted agents and immunotherapies with established regimens.

• NSCLC across early-stage, locally advanced, and metastatic settings
• Small cell lung cancer in first-line and relapsed disease
• Molecular targets such as KRAS G12C, ALK, ROS1, EGFR, and RET
• Studies designed to measure tumor response, progression-free survival, and overall survival

These trials aim to refine how lung cancer is treated by matching therapies to tumor biology and by testing combinations that may improve control of advanced disease.

Research at this site also covers key genitourinary oncology topics, including bladder cancer, urothelial carcinoma, and prostate cancer. The studies are focused on finding better options for both localized and advanced disease, especially where current treatments leave important unmet needs.

• Bladder cancer, including non-muscle-invasive, muscle-invasive, and metastatic forms
• Prostate cancer, including high-risk, metastatic, and castration-resistant disease
• Trials exploring bladder-preserving approaches and new systemic therapies
• Evaluation of treatment effectiveness, disease control, and event-free survival

The Oncologia Medica 2 team is contributing to efforts that may improve both cancer control and treatment choices for patients with challenging urinary tract and prostate malignancies.

This research portfolio includes studies in breast cancer, endometrial cancer, cervical cancer, and ovarian cancer. The trials are designed to test newer treatment combinations, support adjuvant care, and reduce the risk of recurrence in patients with hormone-sensitive or advanced disease.

• Early and metastatic breast cancer, including hormone receptor-positive and HER2-negative disease
• Endometrial, cervical, and ovarian cancers
• Studies of immunotherapy, endocrine therapy, and targeted therapy combinations
• Research focused on recurrence prevention and survival improvement

These trials are helping clarify how best to personalize care for women’s cancers, from early treatment decisions to management of recurrent or advanced disease.

The site runs clinical trials in melanoma and selected skin and connective tissue diseases, including vitiligo, hidradenitis suppurativa, and inflammatory skin conditions. Research in this area includes both cancer treatment and symptom-focused studies aimed at improving quality of life.

• Melanoma, including resected, unresectable, and metastatic disease
• Vitiligo and hidradenitis suppurativa
• Testing new immunotherapy and supportive treatment approaches
• Evaluating symptom control, disease response, and long-term tolerability

This mix of oncology and dermatology research reflects a broader effort to address both aggressive cancers and chronic skin disorders with better-targeted care.

Clinical research at I.F.O. Istituti Fisioterapici Ospitalieri also includes hematologic cancers and rarer tumor types such as lymphoma, acute leukemia, multiple myeloma, sarcoma, and meningioma. These studies often address patients with relapsed, refractory, or high-risk disease.

• Lymphomas, acute leukemias, and multiple myeloma
• Sarcomas, meningiomas, and other uncommon cancers
• Trials assessing new therapies for hard-to-treat or recurrent disease
• Focus on tumor response, survival outcomes, and long-term disease control

These studies expand treatment possibilities for patients with rare or complex cancers where therapeutic options are often limited.